Do analysts recommend VBIO or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VBIO or NDRA more profitable?

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -138.10% -63.67% ENDRA Life Sciences N/A -433.64% -204.58%

Does the media prefer VBIO or NDRA?

In the previous week, Valion Bio, Inc. Common Stock and Valion Bio, Inc. Common Stock both had 1 articles in the media. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat ENDRA Life Sciences' score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valion Bio, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NVNO or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NVNO or VBIO more profitable?

enVVeno Medical's return on equity of -66.39% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -66.39% -60.42% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Do analysts recommend VBIO or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VBIO or QNRX more profitable?

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -138.10% -63.67% Quoin Pharmaceuticals N/A -489.85% -221.29%

Does the media prefer VBIO or QNRX?

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat Quoin Pharmaceuticals' score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valion Bio, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VVOS or VBIO?

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 517.83%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer VVOS or VBIO?

In the previous week, Vivos Therapeutics had 2 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat Vivos Therapeutics' score of 0.81 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XAIR or VBIO?

Beyond Air currently has a consensus target price of $10.00, suggesting a potential upside of 2,036.75%. Given Beyond Air's stronger consensus rating and higher possible upside, research analysts clearly believe Beyond Air is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beyond Air 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Valion Bio, Inc. Common Stock (VBIO) Competitors

$0.50 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

VBIO vs. NDRA, NVNO, QNRX, VVOS, and XAIR

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? MarketBeat compares Valion Bio, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valion Bio, Inc. Common Stock include ENDRA Life Sciences (NDRA), enVVeno Medical (NVNO), Quoin Pharmaceuticals (QNRX), Vivos Therapeutics (VVOS), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Valion Bio, Inc. Common Stock and Valion Bio, Inc. Common Stock both had 1 articles in the media. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat ENDRA Life Sciences' score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ENDRA Life Sciences has lower revenue, but higher earnings than Valion Bio, Inc. Common Stock. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	2.05	-$8.88M	-$6.68	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Valion Bio, Inc. Common Stock has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

Summary

Valion Bio, Inc. Common Stock beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A
Valion Bio, Inc. Common Stock	$780K	2.05	-$8.88M	-$6.68	N/A

enVVeno Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

enVVeno Medical's return on equity of -66.39% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-66.39%	-60.42%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for enVVeno Medical. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat enVVeno Medical's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Neutral
Valion Bio, Inc. Common Stock	Positive

Summary

Valion Bio, Inc. Common Stock beats enVVeno Medical on 7 of the 12 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat Quoin Pharmaceuticals' score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Valion Bio, Inc. Common Stock has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	2.05	-$8.88M	-$6.68	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 2.2% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Valion Bio, Inc. Common Stock beats Quoin Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 517.83%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

In the previous week, Vivos Therapeutics had 2 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat Vivos Therapeutics' score of 0.81 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.36	-$21.17M	-$2.14	N/A
Valion Bio, Inc. Common Stock	$780K	2.05	-$8.88M	-$6.68	N/A

Vivos Therapeutics has a beta of 6.16, indicating that its stock price is 516% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vivos Therapeutics and Valion Bio, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Beyond Air?

Beyond Air (NASDAQ:XAIR) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Beyond Air. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Beyond Air. Valion Bio, Inc. Common Stock's average media sentiment score of 1.11 beat Beyond Air's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Beyond Air	Neutral
Valion Bio, Inc. Common Stock	Positive

Beyond Air has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

Beyond Air currently has a consensus target price of $10.00, suggesting a potential upside of 2,036.75%. Given Beyond Air's stronger consensus rating and higher possible upside, research analysts clearly believe Beyond Air is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$7.68M	0.88	-$33.25M	-$4.40	N/A
Valion Bio, Inc. Common Stock	$780K	2.05	-$8.88M	-$6.68	N/A

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 10.0% of Beyond Air shares are held by insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Beyond Air's net margin of -432.99%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Beyond Air's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beyond Air	-432.99%	-350.00%	-101.34%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Summary

Valion Bio, Inc. Common Stock beats Beyond Air on 9 of the 16 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60M	$1.83B	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.07	81.75	28.02	24.70
Price / Sales	2.05	7.15	540.37	99.46
Price / Cash	N/A	26.08	49.26	57.09
Price / Book	0.08	5.75	10.96	6.46
Net Income	-$8.88M	-$54.76M	$3.57B	$337.01M
7 Day Performance	-10.11%	2.95%	2.12%	1.69%
1 Month Performance	-34.36%	2.81%	5.25%	3.81%
1 Year Performance	-87.32%	-0.07%	33.29%	23.90%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	1.1418 of 5 stars	$0.50 flat	N/A	-87.3%	$1.60M	$780K	N/A	10	News Coverage Short Interest Increase Gap Down
NDRA ENDRA Life Sciences	2.1701 of 5 stars	$6.27 +18.1%	$25.00 +298.7%	+36.6%	$6.74M	N/A	N/A	20	News Coverage High Trading Volume
NVNO enVVeno Medical	1.0796 of 5 stars	$11.57 +18.2%	N/A	-92.1%	$6.54M	N/A	N/A	30	Analyst Downgrade Gap Up
QNRX Quoin Pharmaceuticals	1.1688 of 5 stars	$3.83 +17.8%	N/A	-49.6%	$6.53M	N/A	N/A	4	Gap Up High Trading Volume
VVOS Vivos Therapeutics	2.9691 of 5 stars	$0.44 -5.3%	$2.80 +534.3%	-89.3%	$6.48M	$17.44M	N/A	160	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. NDRA, NVNO, QNRX, VVOS, and XAIR

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

Summary

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

Summary

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Summary

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to Beyond Air?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. NDRA, NVNO, QNRX, VVOS, and XAIR

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

Does the media prefer VBIO or NDRA?

Do analysts recommend VBIO or NDRA?

Do institutionals and insiders have more ownership in VBIO or NDRA?

Which has better valuation and earnings, VBIO or NDRA?

Which has more risk and volatility, VBIO or NDRA?

Is VBIO or NDRA more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

Do institutionals & insiders have more ownership in NVNO or VBIO?

Which has better valuation and earnings, NVNO or VBIO?

Which has more risk & volatility, NVNO or VBIO?

Is NVNO or VBIO more profitable?

Do analysts prefer NVNO or VBIO?

Does the media favor NVNO or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Quoin Pharmaceuticals?

Does the media prefer VBIO or QNRX?

Which has more risk & volatility, VBIO or QNRX?

Is VBIO or QNRX more profitable?

Which has preferable earnings & valuation, VBIO or QNRX?

Do institutionals & insiders have more ownership in VBIO or QNRX?

Do analysts recommend VBIO or QNRX?

Summary

How does Valion Bio, Inc. Common Stock compare to Vivos Therapeutics?

Do analysts recommend VVOS or VBIO?

Is VVOS or VBIO more profitable?

Does the media prefer VVOS or VBIO?

Which has stronger valuation & earnings, VVOS or VBIO?

Which has more risk and volatility, VVOS or VBIO?

Do insiders & institutionals have more ownership in VVOS or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Beyond Air?

Does the media favor XAIR or VBIO?

Which has more volatility and risk, XAIR or VBIO?

Do analysts recommend XAIR or VBIO?

Which has better earnings and valuation, XAIR or VBIO?

Do insiders and institutionals have more ownership in XAIR or VBIO?

Is XAIR or VBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools